Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 23, 2007, Pages 7480-7493

  Cano, Carolina ^a   Goya, Pilar ^a   Paez, Juan Antonio ^a   Girón, Rocío ^b   Sánchez, Eva ^b   Martín, María Isabel ^b  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

1,2,6 Thiadiazine; Cannabinoid; Cannabinoid agonist; Cannabinoid antagonist

Indexed keywords

1,1 DIOXO 1,2,6 THIADIAZINE 5 CARBOXAMIDE DERIVATIVE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPT 2 YL) 2 (2,4 DICHLOROBENZYL) 3 (4 CHLOROPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPT 2 YL) 2 BENZYL 3 (4 CHLORO 3 METHYLPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPT 2 YL) 2 BENZYL 3 (4 CHLOROPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (MORPHOLIN 1 YL) 2 BENZYL 3 (4 BROMOPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (MORPHOLIN 1 YL) 2 BENZYL 3 METHYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL )2 BENZYL 3 (4 CHLOROPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 (2,4 DICHLOROBENZYL) 3 (4 BROMOPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 (2,4 DICHLOROBENZYL) 3 (4 CHLOROPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 (4 CHLOROPHENYL) 3 METHYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 BENZYL 3 (4 BROMOPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 BENZYL 3 (4 CHLORO 3 METHYLPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 BENZYL 3 METHYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 CYCLOHEXYL 3 METHYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 2 HEXYL 3 METHYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 3 (4 BROMOPHENYL) 2 CYCLOHEXYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N (PIPERIDIN 1 YL) 3 (4 CHLOROPHENYL) 2 HEXYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N CYCLOHEXYL 2 (2,4 DICHLORBENZYL) 3 (4 CHLORO 3 METHYLPHENUL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N CYCLOHEXYL 2 PHENYL 3 METHYL 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; N PHENYL 2 BENZYL 3 (4 CHLOROPHENYL) 1,1 DIOXO 1,2 DIHYDRO 1 LAMBDA6 1,2,6 THIADIAZINE 5 CARBOXAMIDE; RIMONABANT; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BIOASSAY; CARBON NUCLEAR MAGNETIC RESONANCE; CATALEPSY; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; HOT PLATE TEST; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; MUSCLE CONTRACTION; NONHUMAN; OPEN FIELD TEST; PROTON NUCLEAR MAGNETIC RESONANCE; RECTUM TEMPERATURE; VAS DEFERENS;

ANIMALS; BENZOXAZINES; CANNABINOIDS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HYPOTHERMIA; INJECTIONS, INTRAPERITONEAL; LOCOMOTION; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; MORPHOLINES; NAPHTHALENES; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; STEREOISOMERISM; THIADIAZINES; VAS DEFERENS;

MUS;

EID: 35148892801     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.07.056     Document Type: Article

References (59)

1. Gaoni Y., and Mechoulam R. J. Am. Chem. Soc. 86 (1964) 1646-1647
2. Thakur G.A., Duclos Jr. R.I., and Makriyannis A. Life Sci. 78 (2005) 454-466
3. Thakur G.A., Nikas S.P., and Makriyannis A. Mini Rev. Med. Chem. 5 (2005) 631-640
4. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Grin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Science 258 (1992) 1946-1949
5. Di Marzo V. Trends Pharmacol. Sci. 27 (2006) 134-140
6. Smith R.A., and Fathi Z. IDrugs 8 (2005) 53-66
7. Pertwee R.G. Handb. Exp. Pharmacol. 168 (2005) 1-51
8. Pertwee R.G. Life Sci. 76 (2005) 1307-1324
9. Padgett L.W. Life Sci. 77 (2005) 1767-1798
10. Huffman J.W. Mini Rev. Med. Chem. 5 (2005) 641-649
11. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Nature 346 (1990) 561-564
12. Munro S., Thomas K.L., and Abu-Shaar M. Nature 365 (1993) 61-65
13. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., et al. Pharmacol. Ther. 106 (2005) 133-145
14. Baker D., Pryce G., Davies W.L., and Hiley C.R. Trends Pharmacol. Sci. 27 (2006) 1-4
15. Brown, A. J.; Wise, A. Glaxosmithkline. Identification of modulators of GPR55 activity. WO0186305. 2001.
16. Drmota, T. G., Peter; Groblewski, Thierry. Astrazeneca. Screening assays for cannabinoid-ligand type modulators of GPR55. Ge: PCT Int. Appl. WO 2004074844 A1 2 Sep 2004, 2004.
17. Patny A., Desai P.V., and Avery M.A. Curr. Med. Chem. 13 (2006) 1667-1691
18. Montero C., Campillo N.E., Goya P., and Paez J.A. Eur. J. Med. Chem. 40 (2005) 75-83
19. Bifulco M., Laezza C., Pisanti S., and Gazzerro P. Br. J. Pharmacol. 148 (2006) 123-135
20. Hall W., Christie M., and Currow D. Lancet Oncol. 6 (2005) 35-42
21. Barnes M.P. Exp. Opin. Pharmacother. 7 (2006) 607-615
22. Carai M.A., Colombo G., and Gessa G.L. Life Sci. 31 (2005) 31
23. Goya P., Jagerovic N., Hernandez-Folgado L., and Martin M.I. Mini Rev. Med. Chem. 3 (2003) 765-772
24. Elguero J., Ochoa C., Stud M., Esteban Calderón C., Martínez Ripoll M., Fayet J.P., and Vertut M.C. J. Org. Chem. 47 (1982) 536-544
25. Pertwee R.G., Stevenson L.A., Elrick D.B., Mechoulam R., and Corbett A.D. Br. J. Pharmacol. 105 (1992) 980-984
26. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., and Ward S.J. Pharmacol. Biochem. Behav. 40 (1991) 471-478
27. Wiley J.L., and Martin B.R. Eur. J. Pharmacol 471 (2003) 185-193
28. Páez, J. A.; Goya, P.; Cano, C.; Martín, M. I.; Girón, M. R; Goicoechea, C. Derivados de 1,1-dioxo-1,2,6-tiadiazina-5-carboxamida de estructura química I y de 1,1-dioxo-1,2,6-tiadiazina-5-carboxilato de alquilo de estructura química II, con propiedades cannabinoides. Pat. Esp. 200502759, 2005.
29. Wright J.B. J. Org. Chem. 29 (1964) 1905-1909
30. Wright, J. B. 3-Carbalkoxy and 3-carbamoyl-5-substituted-2H-1,2,6-thiadiazine-1,1-dioxides and process. Patent, Upjohn Co. U.S. 3223703, 1963; Chem. Abstr. 1966, 64, 8218.
31. Lange J.H., and Kruse C.G. Drug Discov. Today 10 (2005) 693-702
32. Chen J.Z., Han X.W., Liu Q., Makriyannis A., Wang J., and Xie X.G. J. Med. Chem. 26 (2006) 625-636
33. Paquin A.M. Angew. Chem.-Ger. Ed. 60 (1948) 316-320
34. Houlihan, W. J. Chlorobenzylsulfamides. U.S. Patent Application 3,320,314, 1967.
35. Mcdermott S.D., and Spillane W.J. Synthesis-Stuttgart (1983) 192-195
36. Lee C.H., and Kohn H. J. Org. Chem. 55 (1990) 6098-6104
37. Graf R. Chem. Ber-Recl. 92 (1959) 509-513
38. Iwanami Y., and Seki T. Bull. Chem. Soc. Jpn. 45 (1972) 2829-2834
39. Gardner T.S., Lee J., and Wenis E. J. Org. Chem. 26 (1961) 1514-1518
40. Seltzman H.H., Foster M.C., Wyrick C.D., Burgess J.P., and Carroll F.I. J. Label. Compd. Radiopharm. 48 (2005) 589-596
41. Benderly A., and Stavchansky S. Tetrahedron Lett. 29 (1988) 739-740
42. Basha A., Lipton M., and Weinreb S.M. Tetrahedron Lett. (1977) 4171-4174
43. Thomas A., and Pertwee R.G. Methods Mol. Med. 123 (2006) 191-207
44. Pertwee R., Griffin G., Fernando S., Li X., Hill A., and Makriyannis A. Life Sci. 56 (1995) 1949-1955
45. Pertwee R., Griffin G., Lainton J.A., and Huffman J.W. Eur. J. Pharmacol. 284 (1995) 241-247
46. Ross R.A., Gibson T.M., Stevenson L.A., Saha B., Crocker P., Razdan R.K., and Pertwee R.G. Br. J. Pharmacol. 128 (1999) 735-743
47. Schlicker E., Redmer A., Werner A., and Kathmann M. Br. J. Pharmacol. 140 (2003) 323-328
48. Jagerovic N., Hernandez-Folgado L., Alkorta I., Goya P., Martin M.I., Dannert M.T., Alsasua A., Frigola J., Cuberes M.R., Dordal A., and Holenz J. Eur. J. Med. Chem. 41 (2006) 114-120
49. Colombo G., Agabio R., Lobina C., Reali R., and Gessa G.L. Eur. J. Pharmacol. 344 (1998) 67-69
50. Gessa G.L., Casu M.A., Carta G., and Mascia M.S. Eur. J. Pharmacol. 355 (1998) 119-124
51. Sim-Selley L.J., Brunk L.K., and Selley D.E. Eur. J. Pharmacol. 414 (2001) 135-143
52. Mato S., Pazos A., and Valdizan E.M. Eur. J. Pharmacol. 443 (2002) 43-46
53. Savinainen J.R., Saario S.M., Niemi R., Jarvinen T., and Laitinen J.T. Br. J. Pharmacol. 140 (2003) 1451-1459
54. Fride E., Perchuk A., Hall F.S., Uhl G.R., and Onaivi E.S. Methods Mol. Med. 123 (2006) 269-290
55. Martin B.R., Thomas B.F., and Razdan R.K. Structural Requirements for Cannabinoid Receptor Probes. In: Pertwee R.G. (Ed). Cannabinoid Receptors (1995), Academic Press, London 35-86
56. Hughes J., Kosterlitz H.W., and Leslie F.M. Br. J. Pharmacol. 53 (1975) 371-381
57. Pertwee R.G. Br. J. Pharmacol. 46 (1972) 753-763
58. Arunlakshana O., and Schild H.O. Br. J. Pharmacol. Chemother. 14 (1959) 48-58
59. Maruyama I., Tomiyama Y., Maruyama K., Ojima K., Kobayashi K., Kobayashi M., Yamazaki Y., Kojima M., and Shibata N. Eur. J. Pharmacol. 531 (2006) 194-200